116
Views
18
CrossRef citations to date
0
Altmetric
Original Research

Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice

, , , , , , , , , & show all
Pages 1493-1503 | Published online: 20 Feb 2015

References

  • World Malaria Report 2013GenevaWorld Health Organization2013
  • IdroRMarshKJohnCCNewtonCRCerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcomePediatr Res201068426727420606600
  • SchlitzerMAntimalarial drugs – what is in use and what is in the pipelineArch Pharm (Weinheim)200834114916318297679
  • AlonsoPLBrownGArevalo-HerreraMA research agenda to underpin malaria eradicationPLoS Med201181e100040621311579
  • LawrenceMJReesGDMicroemulsion-based media as novel drug delivery systemsAdv Drug Deliv Rev2000458912111104900
  • PetersWRobinsonBLMilhousWKThe chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605Ann Trop Med Parasitol1993875475528122915
  • BruecknerRPLasseterKCLinETSchusterBGFirst-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarialAm J Trop Med Hyg1998586456499598455
  • WhiteNJPrimaquine to prevent transmission of falciparum malariaLancet infect Dis201313217518123182932
  • CrockettMKainKCTafenoquine: a promising new antimalarial agentExpert Opin Investig Drugs2007165705715
  • WhiteNJThe role of anti-malarial drugs in eliminating malariaMalar J20087Suppl 1S819091042
  • ColemanREClavinAMMilhousWKGametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR Mice and Anopheles stephensi mosquitoesAm J Trop Med Hyg1992461691821539752
  • VennerstromJLNuzumEOMillerRE8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerizationAntimicrob Agents Chemother19994359860210049273
  • ShanksGDOlooAJAlemanGMA new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malariaClin Infect Dis2001331968197411700577
  • WalshDSEamsilaCSasipraphaTEfficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malariaJ Infect Dis20041901456146315378438
  • CappelliniMDFiorelliGGlucose-6-phosphate dehydrogenase deficiencyLancet2008371647418177777
  • NkhomaETPooleCVannappagariVHallSABeutlerEThe global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysisBlood Cells Mol Dis200942326727819233695
  • TishkoffSAVarkonyiRCahinhinanNHaplotype diversity and linkage disequilibrium at human G6PD: recent origin of alleles that confer malarial resistanceScience200129345546211423617
  • RochfordROhrtCBareselPCHumanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicityPNAS201311043174861749124101478
  • NobleSMarkhamACyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral)Drugs1995509249418586033
  • KovarikJMMuellerEAvan BreeJBTetzloffWKutzKReduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulationJ Pharm Sci1994834444468207699
  • ErkkoPGranlundHNuutinenMReitamoSComparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasisBr J Dermatol199713682889039300
  • TragerWJensenJBHuman malaria parasites in continuous cultureScience1976193673675781840
  • MaklerMTRiesJMWilliamsJAParasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivityAm J Trop Med Hyg1993487397418333566
  • BealSLSheinerLBBoeckmannAJNONMEM Users Guides. 1989–2006Ellicott City, MA, USAIcon Development Solutions
  • LindbomLRibbingJJonssonENPerl-speaks-NONMEM (PsN) – a Perl module for NONMEM related programmingComput Methods Programs Biomed2004752859415212851
  • JonssonENKarlssonMOXpose – an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMComput Methods Programs Biomed1999581516410195646
  • KeizerRJvan BentenMBeijnenJHSchellensJHHuitemaADPiraña and PCluster: a modeling environment and cluster infrastructure for NONMEMComput Methods Programs Biomed20111011727920627442
  • HolfordNThe visual predictive check – superiority to standard diagnostic (Rorschach) plotsPAGE 14 Abstr738. Abstracts of the Annual Meeting of the Population Approach Group in EuropeJune 16–17, 2005Pamplona Available from: http://www.page-meeting.org/?abstract=738Accessed January 22, 2013
  • AndersonBJHolfordNHMechanism-based concepts of size and maturity in pharmacokineticsAnnu Rev Pharmacol Toxicol20084830333217914927
  • Guide for the Care and Use of Laboratory AnimalsWashington, DCNational Academies Press2010 Available from: http://grants.nih.gov/grants/olaw/Guide-for-the-care-and-use-of-laboratory-animals.pdfAccessed February 13, 2015
  • BaroliBLópez-QuintelaMADelgado-CharroMBFaddaAMBlanco-MéndezJMicroemulsions for topical delivery of 8-methox-salenJ Control Release200069120921811018558
  • BugALRSafranSAGrestGSWebmanIDo interactions raise or lower a percolation threshold?Phys Rev Lett1985551896189910031955
  • PradinesBMamfoumbiMMTallAIn vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and DjiboutiAntimicrob Agents Chemother20065093225322616940138
  • LaiJLuYYinZHuFWuWPharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticlesInt J Nanomedicine20105132320161984
  • ShaikhJAnkolaDDBeniwalVSinghDKumarMNNanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancerEur J Pharm Sci2009373–422323019491009
  • SinghKKNanomedicine in malariaSoutoEBPatenting Nanomedicines: Legal Aspects, Intellectual Property and Grant OpportunitiesBerlinSpringer2012401434
  • LuYWuKLiLCharacterization and evaluation of an oral microemulsion containing the antitumor diterpenoid compound ent-11alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acidInt J Nanomedicine201381879188623690685
  • BorhadeVPathakSSharmaSPatravaleVFormulation and characterization of atovaquone nanosuspension for improved oral delivery in the treatment of malariaNanomedicine (Lond)20149564966623927590
  • AkhtarFRizviMMKarSKOral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected miceBiotechnol Adv201230131032021619927
  • WangHLiQReyesSNanoparticle formulations of decoquinate increase antimalarial efficacy against liver stage Plasmodium infections in miceNanomedicine201410576523891618
  • WengTJianpingQYiLuThe role of lipid-based nano delivery systems on oral bioavailability enhancement of fenofibrate, a BCS II drug: comparison with fast-release formulationsJ Nanobiotechnology2014123925248304
  • ElmesNJNasveldPEKitchenerSJKociskoDAEdsteinMDThe efficacy and tolerability of three different regimes of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest PacificTrans R Soc Trop Med Hyg2008102111095110118541280
  • SethiMSukumarRKarveSEffect of drug release kinetics on nanoparticle therapeutic efficacy and toxicityNanoscale2014642321232724418914